| Ref ID | 999 |
| First Author | H. Cao |
| Journal | BMC MEDICAL RESEARCH METHODOLOGY |
| Year Of Publishing | 2024 |
| URL | https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-024-02182-w |
| Keywords |
• Neurology • Gastroenterology • Outcomes • Urology • Musculoskeletal |
| Problem(s) |
• No registered or published protocol • Low methodological (AMSTAR) quality • Limited quality assessment or no risk of bias |
| Article Type | Empirical |
| Article Subtype | Cross-sectional survey/Methodological systematic review |
| First Author Country | China |
| Checklists |
• AMSTAR 2 |
| Aim | To investigate the methodological quality (AMSTAR-2) of Systematic Reviews (SRs) indexed on PubMed from inception to May 2022 that serve as a basis for Core Outcome Set (COS) development and assess the quality of these SRs using complete AMSTAR 2.0. |
| Level of Investigation | Descriptive |
| Summary of Findings | The study included 175 SRs indexed on PubMed from inception to May 2022 focused on five diseases: musculoskeletal system or connective tissue disease, injury or poisoning, digestive system disease, nervous system disease, and genitourinary system disease. Although 88.00% of SRs included randomized controlled trials (RCTs), only a few SRs (23.38%) employed appropriate tools to assess the risk of bias in RCTs. AMSTAR 2.0 assessment indicated that most SRs (93.71%) were rated as ‘’critically low’’ to ‘’low’’ in terms of overall confidence. The overall confidence of SRs with protocols was significantly higher than that without protocols (P <.001). Compared to the SRs with protocols on Core Outcome Measures in Effectiveness Trials (COMET), SRs with protocols on PROSPERO were of better overall confidence (P = .017). |
| Number of systematic reviews included | 175 |
| Number of eligible systematic reviews assessed | 755 |
| Treatment impacted | No |
| Treatment impacted description | |
| Interpretation impacted | Not Applicable |
| Interpretation impacted description |